Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy? - Wikidata - awgldk - TriplyDB

Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?

Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?

http://www.wikidata.org/entity/Q38734501

about

Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.Modelling diabetic nephropathy in mice.Renoprotective Effect of a Chinese Herbal Formula, Qidan Dihuang Decoction, on Streptozotocin-Induced Diabetes in Rat.

P2860

Q33741426-FF270CF0-F6F5-47CF-8A60-918D3466A154 Q47735079-56DA8303-38B4-48C2-B1CD-E0A05FFAE151 Q55360117-D3300913-8145-45C1-A84D-2A903CBB46F5

P2860

Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?

http://www.wikidata.org/entity/Q38734501

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?

@en

type

label

Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?

@en

prefLabel

Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?

@en

P1433

Q38734501-FD050299-3231-49EB-904C-C6FF85D98832

P1476

Q38734501-2571697E-6563-4B23-8504-38BB78A65810

P2093

Q38734501-30398E69-93C7-4971-B6BD-F741E87A702E

Q38734501-469F1BDD-9E6D-43C8-8CC1-67879A1916EB

P2860

Q38734501-03B06412-D913-4410-B82E-7A5EBF0AB531

Q38734501-394E61AD-3DB4-44A6-B1D6-A9684AD0E22C

Q38734501-571EE78D-5FE7-4791-AE6E-1D2FDA208EB6

Q38734501-5BE73F26-3501-4FE3-891D-708E8C04EE0A

Q38734501-6400F554-BBD0-4C4F-8B05-DCC9B9B0C440

Q38734501-66503E08-A0C7-4893-9C12-2F9CD8E45397

Q38734501-6CE29DBD-ED7F-404D-88A2-FD9613A6BDB3

Q38734501-84183C0C-BCE4-41AB-A8BC-DEA214AAC009

Q38734501-8A079C1C-77E8-4A8F-9C9F-FC6471D03BB0

Q38734501-9A11A011-2C8E-4362-BAAC-D4429B162D9F

P2888

Q38734501-6786A246-2280-483D-B3A2-5281C8FA2571

P304

Q38734501-DF0B5A41-0315-484D-B675-C932F7E32EF4

P31

Q38734501-6D6ABD8E-DB66-44C8-9F60-5E2E61118F13

P356

Q38734501-50FEFA61-1F9F-4F36-9F45-502DFA12DEB0

P433

Q38734501-DBDD4A6F-9C6E-44CE-936F-B8DCA17E81D9

P478

Q38734501-343B0A24-525B-4DD3-AEB9-4421D0E891D1

P577

Q38734501-9D8974C0-30AD-4C6F-8925-FD0A1FED96C8

P5875

Q38734501-37BF68FE-0EA7-46D8-8218-672335429593

P6179

Q38734501-6D820D69-08D1-43E8-944E-2184B8188F44

P698

Q38734501-228EC8DE-DFEE-4D4F-A8FF-117033A1AF03

P356

S11892-016-0713-Y

P1433

Current diabetes report

P1476

Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?

@en

P2093

Collen Majewski

http://www.w3.org/2001/XMLSchema#string

George L Bakris

http://www.w3.org/2001/XMLSchema#string

P2860

Standards of Medical Care in Diabetes--2015: Summary of Revisions

New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Renal and retinal effects of enalapril and losartan in type 1 diabetes

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

Sodium zirconium cyclosilicate in hyperkalemia.

P2888

s11892-016-0713-y

P304

24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11892-016-0713-Y

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

294730039

http://www.w3.org/2001/XMLSchema#string

P6179

1038669485

http://www.w3.org/2001/XMLSchema#string

P698

26879307

http://www.w3.org/2001/XMLSchema#string